Insider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $281,500.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Jeffrey William Henderson sold 5,000 shares of the company’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the sale, the director now owns 38,611 shares of the company’s stock, valued at $2,173,799.30. This represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jeffrey William Henderson also recently made the following trade(s):

• On Monday, January 6th, Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $50.01, for a total value of $500,100.00.

Halozyme Therapeutics Trading Up 0.5 %

NASDAQ:HALO opened at $57.94 on Friday. The company has a market capitalization of $7.37 billion, a P/E ratio of 19.19, a PEG ratio of 0.43 and a beta of 1.25. The firm has a fifty day simple moving average of $51.18 and a 200-day simple moving average of $54.38. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics, Inc. has a 12 month low of $34.36 and a 12 month high of $65.53.

Analyst Ratings Changes

A number of research analysts have commented on HALO shares. JMP Securities raised their target price on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research report on Friday, November 1st. HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Halozyme Therapeutics in a report on Tuesday. Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Finally, Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $60.89.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. RPg Family Wealth Advisory LLC purchased a new position in shares of Halozyme Therapeutics in the 3rd quarter valued at about $1,886,000. Segall Bryant & Hamill LLC increased its holdings in shares of Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock valued at $20,330,000 after purchasing an additional 49,856 shares during the last quarter. Retirement Systems of Alabama raised its holdings in shares of Halozyme Therapeutics by 23.5% during the 3rd quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after acquiring an additional 74,173 shares during the period. South Street Advisors LLC acquired a new position in Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Finally, Creative Planning grew its position in Halozyme Therapeutics by 43.2% in the second quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after acquiring an additional 11,249 shares during the period. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.